A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (ERN/LRPT) in Patients with Dyslipidemia
- Registry ID
- EUCTR2009-012772-27
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE4
- Sponsor
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- Start date
- 2009-11-19
- Completion date
- 2011-01-14
- Last update
- 2026-08-16
Conditions
- Dyslipidemia
- Dyslipidemia. Dislipidemia
Summary
Main objective: Assess the effects of ERN/LRPT relative to ERN on flushing during the post-withdrawal dosing period as measured by number of days/week with GFSS >4 during weeks 21 to 32.
Locations
- , , Denmark
- , , Spain
- , , Germany
- , , Sweden
- , , Finland
- , , Austria
- , , France
Related clinical trials
- A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
- Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
- Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD
- A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers
- Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD
View on source registry